3-(3-nitrophenyl)isoxazol-5(4H)-one | 103029-79-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3-nitrophenyl)isoxazol-5(4H)-one
• 英文别名: 3-(3-nitrophenyl)-4H-1,2-oxazol-5-one
• CAS: 103029-79-4
• 化学式: C₉H₆N₂O₄
• 分子量: 206.158
• InChiKey: ZWIMTHXIVAFKAH-UHFFFAOYSA-N

物化性质

• 熔点：
  150 °C
• 沸点：
  335.5±44.0 °C(Predicted)
• 密度：
  1.53±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  84.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(3-nitrophenyl)isoxazol-5(4H)-one 在 四乙基氯化铵 、 氯化铵 、 锌 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 2.5h， 生成 3-(5-methoxyisoxazol-3-yl)aniline
  参考文献：
  名称：

  WO2020168148A5

  摘要：

  公开号：

  WO2020168148A5
• 作为产物：
  描述：

  3-硝基苯甲酰乙酸乙酯 在 盐酸羟胺 作用下， 以 乙醇 为溶剂， 生成 3-(3-nitrophenyl)isoxazol-5(4H)-one
  参考文献：
  名称：

  Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1)

  摘要：

  The synthesis and biological evaluation of a series of nonpeptidic small molecule antagonists of the human platelet thrombin receptor (PAR-1) are described. Optimization of the 5-amino-3-arylisoxazole lead resulted in an approximate 100-fold increase in potency. The most potent of these compounds (54) inhibits platelet activation with IC50S of 90 nM against the thrombin receptor agonist peptide (TRAP) and 510 nM against thrombin as the agonist. Further, antagonist 54 fully blocks platelet aggregation stimulated by 1 nM thrombin for 10 min. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(01)00745-4

文献信息

• Substituted bicyclic compounds as farnesoid X receptor modulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US11254663B2

  公开（公告）日：2022-02-22

  Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  公开的是式 (I) 化合物： 或其立体异构体、同系物、盐或溶液，其中所有变量如本文所定义。这些化合物可调节法尼类固醇 X 受体（FXR）的活性，例如作为激动剂。还公开了包含这些化合物的药物组合物，以及通过使用这些化合物和药物组合物治疗与 FXR 失调相关的疾病、紊乱或病症的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性紊乱。
• WO2020168143A5
  申请人：——

  公开号：WO2020168143A5

  公开（公告）日：2022-12-22
• Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis
  作者：Susheel J. Nara、Srinivas Jogi、Srinivas Cheruku、Sarkunam Kandhasamy、Firoz Jaipuri、Pavan Kalyan Kathi、Subba Reddy、Sanket Sarodaya、Erica M. Cook、Tao Wang、Doree Sitkoff、Karen A. Rossi、Max Ruzanov、Susan E. Kiefer、Javed A. Khan、Mian Gao、Satyanarayana Reddy、Sankara Sivaprasad LVJ、Ramola Sane、Kathy Mosure、Xiaoliang Zhuo、Gary G. Cao、Milinda Ziegler、Anthony Azzara、John Krupinski、Matthew G. Soars、Bruce A. Ellsworth、Dean A. Wacker

  DOI：10.1021/acs.jmedchem.2c00165

  日期：2022.7.14
• SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3924337A1

  公开（公告）日：2021-12-22
• [EN] SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR FARNÉSOÏDE X
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2020168148A1

  公开（公告）日：2020-08-20

  Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.